Dr. Zibelman on Determining Treatments for Patients with RCC

Matthew R. Zibelman, MD
Published: Tuesday, Oct 03, 2017



Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses determining treatments for patients with renal cell carcinoma (RCC).

After standard therapy with tyrosine kinase inhibitors (TKIs), there is currently no good data to guide what regimen should come next, states Zibelman. Nivolumab (Opdivo) has been well tolerated, which has made it appealing to many patients. Additionally, patients with bone metastases tend to respond well to cabozantinib (Cabometyx).
 
SELECTED
LANGUAGE


Matthew R. Zibelman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses determining treatments for patients with renal cell carcinoma (RCC).

After standard therapy with tyrosine kinase inhibitors (TKIs), there is currently no good data to guide what regimen should come next, states Zibelman. Nivolumab (Opdivo) has been well tolerated, which has made it appealing to many patients. Additionally, patients with bone metastases tend to respond well to cabozantinib (Cabometyx).
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x